What does this TikTok creator claim?
@sierra.robichaud says her Wegovy side effects are "pretty mild" and "very manageable" after 18 months on the medication. She contrasts this with more difficult side effects early in her treatment journey.
The video shows her discussing ongoing side effects but emphasizes they've become easier to handle over time. Sierra suggests this improvement makes continuing the medication straightforward for her.
Does the timeline match what we know about Wegovy?
Yes, Sierra's experience matches clinical trial data showing side effects typically peak early then diminish. The STEP 1 trial (Wilding et al., NEJM, 2021) found most gastrointestinal side effects occurred during dose escalation in the first 16-20 weeks.
Nausea affected 44.2% of participants on 2.4mg semaglutide versus 16.6% on placebo. But these rates dropped significantly after reaching maintenance dose. Vomiting peaked at 24.6% during escalation, then fell to single digits by week 68.
The study's withdrawal rate tells a similar story. Most people who quit due to side effects (7% total) did so in the first six months, not after sustained treatment.
What about her claim that side effects are "manageable"?
This is subjective but supported by real-world data. The STEP trials showed 83.5% of people stayed on 2.4mg semaglutide for the full 68 weeks, suggesting most found side effects tolerable long-term.
However, Sierra doesn't mention what specific side effects she's experiencing now. The most common persistent effects in trials were nausea (17.4% at one year), diarrhea (11.5%), and constipation (11.1%).
Her experience isn't universal though. About 4.5% of STEP 1 participants stopped treatment due to gastrointestinal issues that didn't resolve. Some people never adapt to the medication.
What's missing from her take?
Sierra focuses entirely on tolerability without discussing effectiveness maintenance. The STEP extension study (Rubino et al., Diabetes Care, 2022) showed people regained about two-thirds of lost weight when stopping semaglutide after one year.
She also doesn't mention the need for ongoing medical monitoring. Long-term Wegovy users need regular check-ins for potential issues like gallbladder problems, which occurred in 2.6% of STEP 1 participants versus 1.2% on placebo.
The cost factor gets ignored too. At roughly $1,300 monthly without insurance coverage, "easy to continue" assumes significant financial resources most people don't have.
What should you actually expect on Wegovy?
Most people do see side effects improve after the initial dose escalation period, just like Sierra describes. But don't expect them to disappear completely.
The STEP 1 data shows about 15-20% of people still experience nausea at one year. Digestive issues remain the most common ongoing complaints. Some people develop new side effects like hair loss or changes in taste.
If you're considering Wegovy, discuss realistic expectations with your doctor. The medication works best when combined with lifestyle changes, and stopping it typically leads to weight regain. Sierra's positive experience is encouraging but not guaranteed for everyone.